PDCD1 and melanoma: They assessed a [89Zr] labeled anti-mouse PD-L1 mAb and dynamic immuno-PET/CT imaging of two murine tumor models (head and neck squamous cell carcinoma and melanoma), alone and during anti-PD-1 mAb immunotherapy.